Marine Drugs (Sep 2024)

Regulation of Safracin Biosynthesis and Transport in <i>Pseudomonas poae</i> PMA22

  • J. Gerardo Hernández Delgado,
  • Miguel G. Acedos,
  • Fernando de la Calle,
  • Pilar Rodríguez,
  • José Luis García,
  • Beatriz Galán

DOI
https://doi.org/10.3390/md22090418
Journal volume & issue
Vol. 22, no. 9
p. 418

Abstract

Read online

Pseudomonas poae PMA22 produces safracins, a family of compounds with potent broad-spectrum anti-bacterial and anti-tumor activities. The safracins’ biosynthetic gene cluster (BGC sac) consists of 11 ORFs organized in two divergent operons (sacABCDEFGHK and sacIJ) that are controlled by Pa and Pi promoters. Contiguous to the BGC sac, we have located a gene that encodes a putative global regulator of the LysR family annotated as MexT that was originally described as a transcriptional activator of the MexEF-OprN multidrug efflux pump in Pseudomonas. Through both in vitro and in vivo experiments, we have demonstrated the involvement of the dual regulatory system MexT-MexS on the BGC sac expression acting as an activator and a repressor, respectively. The MexEF-OprN transport system of PMA22, also controlled by MexT, was shown to play a fundamental role in the metabolism of safracin. The overexpression of mexEF-oprN in PMA22 resulted in fourfold higher production levels of safracin. These results illustrate how a pleiotropic regulatory system can be critical to optimizing the production of tailored secondary metabolites, not only through direct interaction with the BGC promoters, but also by controlling their transport.

Keywords